文献速递消化系统肿瘤

替西木单抗联合度伐利尤单抗作为微卫星高度不稳定可切除胃或胃食管结合部腺癌的新辅助或非手术治疗策略:GONO的INFINITY研究

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
PubMed 文献 · Ann Oncol · 2024-12-03

INFINITY是多中心、多队列II期试验,评估替西木单抗联合度伐利尤单抗(T300/D)在错配修复缺陷/MSI-H可切除胃或胃食管结合部腺癌中的疗效与安全性。队列1新辅助治疗中pCR率60%、主要病理缓解率80%,T4肿瘤pCR率17%故被排除于队列2入组;队列2非手术治疗中12例无胃切除生存率64.2%。

要点

  • 队列1新辅助T300/D的pCR率为60%,主要病理缓解率为80%。
  • T4肿瘤pCR率17%,该亚组被排除于队列2入组。
  • 队列2非手术治疗中12个月无胃切除生存率为64.2%。

核心结论

  • 无化疗的T300/D联合方案作为错配修复缺陷/MSI胃或胃食管结合部腺癌的术前治疗显示出有前景的活性,并首次提供了该疾病背景下非手术治疗策略的可行性结果,值得在更大队列中进一步验证。

研究设计与样本

  • INFINITY为多中心、多队列II期试验(NCT04817826)。
  • 队列1评估T300/D作为错配修复缺陷/MSI-H可切除胃或胃食管结合部腺癌新辅助治疗的活性和安全性。
  • 队列2探索T300/D在达到临床完全缓解(cCR)患者中作为确定性治疗的活性和安全性。

主要发现

  • 队列1入组18例、可评估15例,pCR率和主要病理缓解-pCR分别为60%和80%,T4肿瘤pCR率为17%。
  • 队列1中位随访28.1个月时,24个月胃癌特异性PFS率和OS率分别为85%和92%。
  • 队列2入组18例、可评估17例,13例达cCR并开始非手术治疗。
  • 队列2中位随访11.5个月时,1例局部再生长并接受挽救手术,12个月无胃切除生存率为64.2%。

关键数值与推荐

  • 队列1主要终点为pCR率;次要终点包括PFS、OS、生活质量和转化分析。
  • 队列2主要终点为2年cCR率;次要终点包括PFS、OS、生活质量、无胃切除生存和转化分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出结果值得在更大队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit from chemotherapy. Immunotherapy may eliminate the need for chemotherapy or surgery. PATIENTS AND METHODS: INFINITY is a multicenter, multicohort phase II trial (NCT04817826) investigating in cohort 1 the activity and safety of tremelimumab + durvalumab (T300/D) as neoadjuvant treatment of mismatch repair deficient/MSI-H, resectable gastric/gastroesophageal junction adenocarcinoma. Primary endpoint was pathologic complete response (pCR) rate; Secondary endpoints: progression-free survival (PFS), overall survival (OS), quality of life, and translational analyses. In cohort 2, the activity and safety of T300/D was explored as definitive treatment in patients achieving clinical complete response (cCR). Primary endpoint was 2-year cCR rate, and secondary endpoints were PFS, OS, quality of life, gastrectomy-free survival and translational analyses. RESULTS: In cohort 1, 18 patients were recruited and 15 evaluable. pCR and major pathologic response-pCR were 60% and 80%, respectively. Since pCR rate in T4 tumors was 17%, this subgroup of patients was excluded from enrollment in cohort 2. At 28.1 months median follow-up, 24-month gastric cancer-specific PFS and OS rates were 85% and 92%, respectively. In cohort 2, 18 patients were enrolled and 17 assessable, and 13 had cCR and started non-operative management. At 11.5 months median follow-up, one patient had local regrowth and underwent salvage surgery; 12-month gastrectomy-free survival was 64.2%. CONCLUSIONS: The INFINITY study provided promising activity results of a chemo-free T300/D combination regimen as preoperative treatment in mismatch repair deficient/MSI gastric/gastroesophageal junction adenocarcinoma and the first available feasibility results of a non-operative management strategy in this disease setting, worthy of further validation in larger cohorts.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Raimondi A, Lonardi S, Murgioni S, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann Oncol. 2024. PMID: 39637944. doi:10.1016/j.annonc.2024.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。